	Les Charges D'Exploitation		Date
AbbVie	USD 10.81B	13.45B	2025-12
Agenus	USD -274.14M	80.46M	2025-09
Amgen	USD 5.9B	773M	2025-12
AstraZeneca	USD 12.53B	4.16B	2025-12
Bristol-Myers Squibb	USD 8.3B	10.25B	2025-12
Celldex Therapeutics	USD 87.27M	511.09M	2025-12
CSL	USD 5.7B	2.82B	2025-12
Eli Lilly	USD 10.31B	1.09B	2025-12
Gilead Sciences	USD 4.96B	707M	2025-12
GlaxoSmithKline	GBP 7.18B	1.42B	2025-12
Glaxosmithkline	GBP 7.77B	2.22B	2025-09
Incyte	USD 1.12B	3.53B	2025-12
Intrexon	USD 61.56M	26.1M	2024-06
J&J	USD 18.97B	2.38B	2025-12
Jiangsu Hengrui	CNY 5.94B	254.97M	2025-09
Karyopharm Therapeutics	USD 61.82M	3.24M	2024-12
MacroGenics	USD 67M	8M	2025-09
Merck	EUR 4.11B	117M	2025-09
Merck	USD 10.16B	558M	2025-12
Northwest Biotherapeutics	USD -108.65M	8.26M	2025-09
Novartis	USD 9.86B	115M	2025-09
Novavax	USD 218.53M	34.86M	2024-09
Pfizer	USD 12.91B	79.89B	2025-12
Regeneron Pharmaceuticals	USD 2.99B	27.97B	2025-12
Rigel Pharmaceuticals	USD 117.61M	35.67M	2025-09
Sangamo BioSciences	USD 33.87M	12.89M	2024-06
Veracyte	USD 116M	7.24M	2025-12

Agenus Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.